Company Analysis
Sign in

Autolus Therapeutics plc (AUTL)

Nasdaq: AUTL · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.3
◀ Past 3.1● Present 5.3▶ Future 4.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$75.4M+644.9%
Net income-$288M-30.3%
Earnings per share$-1.08-25.6%
Operating cash flow-$284M-37.5%
Cash$104M-54.2%
Debtn/a
Shareholders’ equity$178M-58.3%
Shares, diluted266.1M+4.3%
Return on equity-161.4%
The recordfrom its filings
Filings in 202673
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportMar 27, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted55
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $137MNet income -$256MCash from operations -$176Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 22, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Sep 22, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form DEL AM
Form DEL AM
Open the filing on sec.gov
Sep 14, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AUTL · research, not advice